Physician

Trevor Feinstein, M.D.

According to 2025 Medicare claims, Trevor Feinstein, M.D. (NPI: 1457545709) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fayette, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30214-2112.

Feinstein's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 760 traditional Medicare patients, billed 254,069 HCPCS/CPT codes, and received $4,090,472 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 4,310 prescription claims across 585 beneficiaries totaling $8,555,010 in drug costs, led by Bexarotene (Bexarotene). DME data shows 51 claims. Open Payments data shows 127 records totaling $535,749. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,360,598 to $4,090,472. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,554,003 to $8,555,010. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,068 to $2,409.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	766	189,421	$2,360,598
2016	695	264,741	$2,657,899
2017	722	252,471	$3,318,892
2018	704	266,605	$3,529,220
2019	740	274,454	$4,087,006
2020	717	226,471	$3,667,030
2021	799	284,620	$3,966,248
2022	775	235,240	$4,286,452
2023	806	290,394	$3,966,136
2024	760	254,069	$4,090,472

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	359	2,747	$1,554,003
2016	392	3,175	$2,103,973
2017	411	3,943	$2,792,888
2018	399	3,565	$3,003,928
2019	430	3,428	$3,516,032
2020	430	3,786	$4,112,322
2021	473	3,915	$5,906,143
2022	505	3,774	$6,528,328
2023	542	4,061	$7,672,410
2024	585	4,310	$8,555,010

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	49	303	$101,724
2016	N/R	230	$66,158
2017	N/R	159	$20,668
2018	N/R	180	$16,426
2019	N/R	157	$13,486
2020	N/R	83	$7,061
2021	N/R	127	$30,421
2022	N/R	60	$1,761
2023	N/R	62	$7,572
2024	N/R	51	$2,362

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	114	599	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	261	516	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	375	504	$58
96372	Injection of drug or substance under skin or into muscle	139	447	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	622	1,395	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Bexarotene	Bexarotene	14	404	$1,172,754
Revlimid	Lenalidomide	56	1,568	$1,016,625
Kisqali	Ribociclib Succinate	55	1,540	$794,611
Erleada	Apalutamide	50	1,500	$742,440
Pomalyst	Pomalidomide	22	616	$496,976

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$1,457
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$441
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$350
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$113

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	104	$80,748	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	23	$455,001	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Trevor Feinstein, M.D.?

Tedicare shows public-source Medicare data for Trevor Feinstein, M.D. (NPI 1457545709), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Trevor Feinstein, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Trevor Feinstein, M.D.?

Trevor Feinstein, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Trevor Feinstein, M.D. have Open Payments data?

Trevor Feinstein, M.D. has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.